Arrow Ventures seeks US$125 million to turn animal health science into treatments
What's the deal? Australia's Arrow VenturesDealroom has a profile for this one. Try Dealroom →is raising up to US$125 million to advance early-stage veterinary science into commercially viable treatments. The firm, founded late last year by veterinary pharmaceutical specialist Nick Bova, targets therapeutics for companion animals and livestock. Once this round closes, Arrow plans a second round.
Why now? Arrow has already backed five animal health biotech companies and fielded nearly 100 approaches from developers worldwide. "More funds were needed to capitalise on the opportunities," Bova said.
What's the endgame? Arrow aims to take promising assets through clinical development, regulatory approval, and towards commercialisation in the US, creating acquisition targets for major animal health companies. "I see this as a repeatable model that can support innovation across the industry," Bova said.
Its five portfolio companies span markets: New Zealand's Hale Animal HealthDealroom has a profile for this one. Try Dealroom →, developing a cannabinoid-based medicine for canine osteoarthritis; US firm NutrivertDealroom has a profile for this one. Try Dealroom →, working on an antibiotic alternative for swine; US-based Velo I, developing anti-inflammatory drugs for pain in companion animals; Cuspis, targeting Cushing's disease in horses; and New Zealand's Cadmus, developing a treatment for dental disease in dogs.
Why it's attractive: Bova argues veterinary therapeutics can offer venture-style returns with lower costs and shorter timelines than human biotech. A human drug can cost hundreds of millions and take 10 to 15 years; an animal therapeutic can reach market for US$5 to US$15 million in four to eight years.
The reason, Bova said, is efficiency: "In veterinary medicine development fewer clinical trials are needed, the trials are generally smaller in size and are commonly 10-50-fold cheaper to run than Phase III human studies." Testing early in the target species also raises the chance of success.
What's the gap? Many programs struggle not for lack of science, but because capital, regulatory execution, and manufacturing readiness rarely arrive together. "Many opportunities are too early or too specialised for the larger animal health companies and generalist VC investors don't have the sector expertise to progress them properly," Bova said.
The signal: With the global animal health market worth an estimated US$50 to US$70 billion a year and few specialist investors active, Arrow is positioning itself in a largely underserved niche — betting that sector expertise, not just capital, is what unlocks veterinary innovation.
